TPM1 Recombinant Monoclonal Antibody

1. Missense variant (p.Leu113Val) in TPM1 causes left ventricular non-compaction with Ebstein anomaly in five members of the family. PMID:29024827
2. miR-107 overexpression promoted U2OS cell viability, migration, and invasion via downregulation of TPM1 and might be through activating the MEK/ERK and NF-kappaB signaling pathways. PMID:28276320
3. Functional effects of substitutions I92T and V95A in actin-binding period 3 of tropomyosin. PMID:29496559
4. This study demonstrated that sarcomeric TPM1 plays vital roles in cardiogenesis and is a suitable candidate gene for screening individuals with isolated congenital heart defects . PMID:28359939
5. Tpm isoforms 1.8/9 are enriched in the lamellipodium of fibroblasts as detected with a novel isoform-specific monoclonal antibody. RNAi-mediated silencing of Tpm1.8/9 led to an increase of Arp2/3 accumulation at the cell periphery and a decrease in the persistence of lamellipodia and cell motility. PMID:27112294
6. TPM1-AS regulates the alternative splicing of TPM1 through an interaction with RBM4 and involves in TPM1-mediated filopodium formation and migration of cancer cells PMID:28754317
7. The impact of tropomyosins on actin filament assembly is isoform specific. PMID:27420374
8. TPM1 is the second gene linked to EA with LVNC in humans, implicating overlap in the molecular basis of structural and myopathic heart disease. PMID:27177193
9. Stress fibre formation and up-regulation of alpha-smooth muscle actin (alphaSMA) induced by TGFbeta2 could be reversed by Tpm1/2 knock-down by siRNA. PMID:27976512
10. data demonstrate that the K15N mutation alters pointed end dynamics by affecting molecular interactions between Tpm1.1, Lmod2 and Tmod1. PMID:28732641
11. Results report evidence for the existence of variants in LHFPL2 and TPM1 with low allele frequencies and large effects on age-at-onset of familial Parkinson's disease. PMID:27402877
12. In diabetes, expression of high molecular weight (HMW) isoforms from tropomyosin 1 (TPM1) were markedly decreased but HMW isoforms from tropomyosin 4 (TPM4) were not significantly different. PMID:27649540
13. results suggest that TPM1 can suppress tumors in oral squamous cell carcinoma, and the TPM1 expression level is related to oral squamous cell carcinoma patient prognosis PMID:28182650
14. Data indicate that various hypertrophic cardiomyopathy (HCM) mutations can differently affect the structural and functional properties of tropomyosin (Tpm) and cause HCM by different molecular mechanisms. PMID:27983818
15. Promoter variants in HOXA9, TPM1, and TPM2, alter promoter expression suggesting that they have a functional role in clubfoot. PMID:27020427
16. The TPM1 mutations D175N and E180G increased the sliding velocity and its calcium sensitivity of the actin-myosin Interaction, while mutation E40K reduced both these parameters. PMID:27878731
17. No association was observed between the remaining three markers (rs11071720, rs3803499, and rs12148828) and NSOC as well as its subgroups. TPM1 polymorphisms might contribute to the etiology ofnonsyndromic orofacial clefts (NSOC), , and more emphasis should be placed on TPM1 during craniofacial development PMID:26792422
18. We propose that TR100 acts to compromise the integrity of Tpm cables rather than prevent overlap complex formation. Our data suggests that TR100 is incorporated into the growing actin-Tpm co-polymer given that its effects cannot be observed on pre-formed Tpm3.1/actin filaments PMID:26804624
19. Structural stabilization of F-actin, by overexpression of tropomyosin-1, preserves cell to cell interactions through the attenuation of cortical actin organization into thin fibers and thus protects these cells against oxidative stress-induced degradation of actin cytoskeleton and cell death. PMID:26805581
20. This is the first report of an association between Familial hypertrophic cardiomyopathy (HCM) and Brugada Syndrome (BrS), and the first to use a combined approach of linkage and NGS to identify a causative mutation in SD. The present study expands the clinical spectrum of disorders associated with theTPM1gene and may be useful to report novel mechanisms of electrical instability in HCM and BrS. PMID:26960954
21. Data confirm that the substitutions of the Tpm1 residues G126 and D137 with the canonical ones, Arg and Leu, respectively, increase the stiffness of the Tpm coiled-coil PMID:26200873
22. these results indicate that TPM1 may be one mechanism underlying radiation resistance, and TPM1 may be a potential target for overcoming the radiation resistance in glioma. PMID:25873252
23. Mitochondrial RNA induces tropomyosin synthesis. PMID:25408381
24. TPM1 exhibits characteristics of a tumor-suppressor gene while being overexpressed in Renal cell carcinoma cell lines. PMID:25607530
25. We have quantified the expression of the total sarcomeric TPM1 and observed a 1.5-fold increase in treated cells. PMID:24958154
26. Coexistence of Digenic Mutations in Both TPM1 and MYH7 Genes Leads to Severe Hypertrophic Cardiomyopathy. PMID:25607779
27. Mutant TPM1cause m ultiple functional alterations in actin affinity and Ca2+ sensitivity. PMID:25548289
28. cardiomyopathy-associated E62Q tropomyosin mutation weakens actin-tropomyosin interaction, but phosphorylation of neighboring S61 rescues the binding-deficit, results confirmed experimentally by in vitro motility assays. PMID:25241052
29. effects of the mutations in the TPM1 gene on hypertrophic cardiomyopathy and dilated cardiomyopathy development (Review) PMID:24005378
30. Vardenafil administration improved erectile functionality in controlled type 2 diabetes mellitus patients with ED, which was associated with reduction of circulating plasma beta-tropomyosin levels. PMID:24112450
31. In addition to CLIC1 and TPM1, which were the proteins initially discovered in a xenograft mouse model, CLIC4, TPM2, TPM3, and TPM4 were present in ovarian cancer patient sera at significantly elevated levels compared with controls. PMID:23792823
32. These data indicated that TPM1 is downregulated in HuCCT1 cells and that the Ras signaling pathway as well as DNA methylation, histone deacetylation and miR-21 upregulation play important roles in the suppression of TPM1 expression in HuCCT1 cells. PMID:23254774
33. Elevated TPM1 and TPM2 expression is associated with epithelial-mesenchymal transition of lens epithelial cells. PMID:23205574
34. TPM1-D175N and myosin-binding protein-Q1061X mutations account for a substantial part of all hypertrophic cardiomyopathy (HCM) cases in the Finnish population. Routine genetic screening of these mutations is warranted in Finnish patients with HCM. PMID:22462493
35. A novel TPM-1 mutation associates with dilated and non-compaction cardiomyopathy and diminishes actin binding. PMID:23147248
36. analysis of the pattern of of evolutionarily conserved basic and acidic residues that constitutes the binding interface of actin-tropomyosin PMID:23420843
37. Expression of low molecular weight isoforms from TPM1 and TPM3 genes is regulated very differently, which has a critical role in processes such as cancer metastasis. PMID:22740512
38. Persistence length of human cardiac alpha-tropomyosin measured by single molecule direct probe microscopy PMID:22737252
39. Familial hypertrophic cardiomyopathy mutation E180G enhances Ca(2+)-sensitivity in functional assays. Increased flexibility of the mutant was confirmed by fitting end-to-end length distributions to the worm-like chain model. PMID:22958892
40. Downregulation of tropomyosin-1 in squamous cell carcinoma of esophagus. PMID:22965424
41. Patients with HCM attributable to D175N mutation of alpha-tropomyosin were studied by CMRI. LV maximal thickness by CMRI is the best parameter in differentiating between LVH due to mild-to-moderate hypertension and HCM attributable to a sarcomeric mutation. PMID:21274714
42. this study compared the bending flexibility of wild-type tropomyosin to that of two mutant tropomyosins, Asp175Asn and Glu180Gly, known to be associated with hypertrophic cardiomyopathy. PMID:22789852
43. variable myocardial and systemic inflammatory response was demonstrated in patients with HCM attributable to an identified sarcometric mutation. PMID:22447464
44. Functional and structural differences in three familial hypertrophic cardiomyopathy-related mutations in recombinant alpha-Tm were characterized using both conventional and modified in vitro motility assays and circular dichroism spectroscopy. PMID:22187526
45. This work studied how the hypertrophic cardiomyopathy-causing Asp175Asn and Glu180Gly mutations in alpha-tropomyosin affect on actin-myosin interaction during the ATPase cycle PMID:22155441
46. identified 5 mutations in cardiac myosin-binding protein C (MYBPC3) and 2 mutations in alpha-tropomyosin (TPM1) in a cohort of unrelated adult probands with isolated left ventricular noncompaction cardiomyopathy PMID:21551322
47. This is the first report of mutations in TPM1, MY L3, and MYL2 associated with primary, non-hypertrophied restrictive cardiomyopathy. PMID:21823217
48. IgE recognition profile of profilins, PR-10 proteins and tropomyosin, were evaluated. PMID:21949785
49. effect of Glu40Lys mutant alpha-tropomyosin on the mobility and rotation of subdomain-1 of actin and the SH1 helix of myosin subfragment-1 during the ATP hydrolysis cycle has been demonstrated PMID:21741356
50. TPM1 is a potential candidate disease-causing gene for isolated LVNC, especially in patients experiencing sudden death. PMID:20965760

Show More

Hide All

HGNC: 12010

UNIGENE: Hs.133892

KEGG: hsa:7168

OMIM: 115196